France at odds with European medicines agency over Pill (Update)

January 3, 2013 in Medications

France insisted Friday on restricting the prescription of newer-generation birth control pills even as Europe's medicines watchdog declared there was no evidence to back a health warning.

Citing concerns over risks of blood clots from the so-called 3rd- and 4th-generation pills, France said it would limit prescriptions of these contraceptives and urged the rest of Europe to follow suit.

Health Minister Marisol Touraine said she would ask the European Medicines Agency (EMA) to "modify" its market authorisation for 3rd- and 4th-generation contraceptive pills.

"The objective is that these pills are no longer prescribed to women as a first option," she said in a statement.

But the EMA earlier said it saw no need to change guidelines.

"There is currently no new evidence that would suggest any change to the known safety profile of any combined contraceptives marketed today," the agency said in a statement from London.

"Therefore, there is no reason for any woman to stop using her contraception."

The 3rd-generation Pill, introduced in the 1990s, and the 4th generation approved in the last decade, contain synthetic versions of the female hormone progestogen and claim to skirt side-effects associated with older versions.

A Danish study published in the British Medical Journal in 2011 found women who took one of the newer types of Pill ran twice the risk of developing blood clots in the veins than those who used older-generation drugs.

Compared with non-users of the Pill, the risk of a clot was between three and six times higher.

Clots formed in the veins can break up and be transported to the heart or lungs and may be fatal.

In absolute terms, though, the risk is small, experts stress.

About 2.5 million women in France take the 3rd- and 4th-generation Pill, about half of all oral contraceptive users—a statistic the French authorities judge excessive.

Touraine said she had asked the National Drugs Safety Agency (ANSM) to release safety data on the Pill and inform health professionals about giving priority to the older, second-generation Pill when prescribing.

The EMA said it had not received new evidence from "any member state" in relation to blood-clot risks, and promised that any information submitted to it would be reviewed promptly.

Under European rules, countries must accept medications that are approved by EMA but this does not prevent national authorities from making recommendations about how the drugs are used.

They are also allowed to temporarily suspend the drugs under the precautionary principle, but cannot ban them unilaterally.

The storm in France was triggered in part by the case of a 25-year-old woman, Marion Larat, who was left badly handicapped by a stroke that, in a lawsuit, she attributed to a later-generation pill made by German firm Bayer.

Her lawyer said in December that 30 other women are likely to file a suit targeting Schering, Merck and Pfizer as well as Bayer.

Some of the 3rd- and 4th-generation pills are already the target of lawsuits and tighter guidelines in the United States.

Last year, Bayer which makes the Yasmin and Yaz contraceptives, said it had spent $750 million to settle nearly 3,500 lawsuits for alleged deep-vein thrombosis or pulmonary embolism.

An estimated 3,800 more lawsuits remain to be settled, as well as nearly 5,000 other claims over other types of injuries allegedly caused by the pills.

In October last year, the US Food and Drug Administration (FDA) required Yasmin, Yaz and two other brands, Beyaz and Safyral, to carry labels warning of a higher risk of clots.

The risks are also influenced by smoking, obesity, diabetes and genes.

The French government has already announced the country's health system will no longer reimburse 3rd- and 4th-generation pills, a measure that will take effect on September 30.

(c) 2013 AFP

5 /5 (1 vote)  

Filter


Move the slider to adjust rank threshold, so that you can hide some of the comments.


Display comments: newest first

Sean_W
Jan 03, 2013

Rank: not rated yet
I'll bet the newer drugs are more expensive and insurers don't want to pay the extra. Or do the old drugs get manufactured locally? It certainly doesn't sound like patient choice or doctors' evaluation is the primary motivation.
Rank 5 /5 (1 vote)
Relevant PhysicsForums posts

More news stories

Feds fight morning-after pill age ruling in NY

(AP)—Department of Justice lawyers have again asked a federal appeals court in New York to delay lifting age restrictions and prescription requirements on an emergency contraceptive popularly known as the morning-after ...

Medications created 17 hours ago | popularity not rated yet | comments 0

Merck ends development of Parkinson's disease drug

(AP)—Merck & Co. says it is ending development of an experimental Parkinson's disease drug because the drug wasn't working.

Medications created May 23, 2013 | popularity 1 / 5 (1) | comments 0

J&J expects 10-plus new drug applications by 2017

(AP)—Johnson & Johnson is developing what could eventually be game-changing treatments for depression and pain, and it's aiming to apply for approval of more than 10 new medicines by 2017, executives said Thursday during ...

Medications created May 23, 2013 | popularity 5 / 5 (1) | comments 0

Experts favor US approval of Merck sleeping pill (Update)

An independent panel of experts on Wednesday recommended US approval of a new Merck sleeping pill called suvorexant, but expressed concerns over the highest dosage and risks of drowsy daytime driving.

Medications created May 22, 2013 | popularity not rated yet | comments 0

Glaxo, US partnering to develop new antibiotics

GlaxoSmithKline PLC says it's starting an unusual collaboration with the U.S. government to develop several antibiotics for both bioterrorism threats and bacterial infections resistant to current medicines.

Medications created May 22, 2013 | popularity not rated yet | comments 0


First drug to improve heart failure mortality in over a decade

Coenzyme Q10 decreases all cause mortality by half, according to the results of a multicentre randomised double blind trial presented today at Heart Failure 2013 congress. It is the first drug to improve heart failure mortality ...

Seniors more likely to crash when driving with pet, study finds

(HealthDay)—Animals make great companions for senior citizens, but elderly people who always drive with a pet in the car are far more likely to crash than those who never drive with a pet, researchers have ...

Heart failure accelerates male 'menopause'

Heart failure accelerates the aging process and brings on early andropausal syndrome (AS), according to research presented today at the Heart Failure Congress 2013. AS, also referred to as male 'menopause', was four times ...

Death highest in heart failure patients admitted in January, on Friday, and overnight

Mortality and length of stay are highest in heart failure patients admitted in January, on Friday, and overnight, according to research presented today at the Heart Failure Congress 2013. The analysis of nearly 1 million ...

New immune system discovered

(Medical Xpress)—A research team, led by Jeremy Barr, a biology post-doctoral fellow, unveils a new immune system that protects humans and animals from infection.

Brain can be trained in compassion, study shows

Until now, little was scientifically known about the human potential to cultivate compassion—the emotional state of caring for people who are suffering in a way that motivates altruistic behavior.